Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab plus SIROX as second-line treatment for previously AG-treated pancreatic cancer
ChiCTR2400084032Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- May 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zimberelimab, oxaliplatin, irinotecan and tegafur in pancreatic cancer (PC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective response rate. Planned start May 2024; status: not yet recruiting.
02
Drugs
zimberelimaboxaliplatinirinotecantegafur
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2400084032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084032.